Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells

Journal of Immunotherapy

Volumn 34, Issue 8, 2011, Pages 569-580

  Smith, Heath A ^a   McNeel, Douglas G ^a  

^a University of Wisconsin Health   (United States)

Author keywords

CTA; CTL; DNA vaccine; epitopes; HLA A21; prostate cancer; SSX 2

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN SSX 2; CANCER TESTIS ANTIGEN SSX 2[103-111]; CANCER TESTIS ANTIGEN SSX 2[41-49]; CANCER VACCINE; CD8 ANTIGEN; DNA VACCINE; EPITOPE; HLA A2 ANTIGEN; HLA DR1 ANTIGEN; PEPTIDE VACCINE; PLASMID DNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GERM LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELLS, CULTURED; EPITOPES; HLA-A2 ANTIGEN; HLA-DR1 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; PEPTIDES; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 80052968146     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31822b5b1d     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Vieweg J. Immunotherapy for advanced prostate cancer. Rev Urol. 2007;9(Suppl 1):S29-S38.
3. McNeel DG. Prostate cancer antigens and vaccines, preclinical developments. Cancer Chemother Biol Response Modif. 2005;22:247-261.
4. Wolchok JD, Gregor PD, Nordquist LT, et al. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol. 2003;30:659-666. (Pubitemid 37296790)
5. Miller AM, Ozenci V, Kiessling R, et al. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormonerefractory prostate cancer. J Immunother. 2005;28:389-395. (Pubitemid 40962333)
6. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27:4047-4054.
7. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol. 2000;38:208-217. (Pubitemid 30452325)
8. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.
9. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001-1011.
10. Monie A, Tsen SW, Hung CF, et al. Therapeutic HPV DNA vaccines. Expert Rev Vaccines. 2009;8:1221-1235.
11. Carvalho JA, Prazeres DM, Monteiro GA. Bringing DNA vaccines closer to commercial use. IDrugs. 2009;12:642-647.
12. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004;91:688-694. (Pubitemid 39141625)
13. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100:2014-2021.
14. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5: 615-625. (Pubitemid 41081387)
15. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells. 2007;25:707-711. (Pubitemid 46354230)
16. Ayyoub M, Taub RN, Keohan ML, et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun. 2004;4:7.
17. Tureci O, Sahin U, Schobert I, et al. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 1996;56:4766-4772. (Pubitemid 26338082)
18. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate. 2007;67:1781-1790. (Pubitemid 350228730)
19. Ayyoub M, Hesdorffer CS, Metthez G, et al. Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. J Immunol. 2004;172:7206-7211. (Pubitemid 38669166)
20. dos Santos NR, Torensma R, de Vries TJ, et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 2000;60: 1654-1662. (Pubitemid 30183438)
21. Wagner C, Neumann F, Kubuschok B, et al. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. Cancer Immun. 2003;3:18.
22. Ayyoub M, Hesdorffer CS, Montes M, et al. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest. 2004;113:1225-1233. (Pubitemid 38544108)
23. Ayyoub M, Merlo A, Hesdorffer CS, et al. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin Immunol. 2005;114:70-78. (Pubitemid 39642792)
24. Viatte S, Alves PM, Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. Immunol Cell Biol. 2006;84:318-330.
25. Ayyoub M, Stevanovic S, Sahin U, et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumorreactive CTL infiltrating metastatic melanoma. J Immunol. 2002;168:1717-1722. (Pubitemid 34135769)
26. Pajot A, Michel ML, Fazilleau N, et al. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol. 2004;34:3060-3069. (Pubitemid 39549385)
27. Perarnau B, Saron MF, San Martin BR, et al. Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur J Immunol. 1999;29:1243-1252. (Pubitemid 29164171)
28. Johnson LE, Frye TP, Arnot AR, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2006;24:293-303. (Pubitemid 41790433)
29. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
30. Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219. (Pubitemid 30099526)
31. Olson BM, Frye TP, Johnson LE, et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010;59:943-953.
32. Sauma SY, Gammon MC, Bednarek MA, et al. Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein. Hum Immunol. 1993; 37:252-258. (Pubitemid 23343714)
33. Ayyoub M, Brehm M, Metthez G, et al. SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immun. 2003;3:13.
34. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175-2182. (Pubitemid 30399182)
35. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgenindependent prostate cancer: a Phase 2 trial. Prostate. 2004; 60:197-204. (Pubitemid 38971831)
36. Small EJ, Schellhammer PF, Higano CS, et al. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094. (Pubitemid 46638945)
37. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
38. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323-5337.
39. Ayyoub M, Rimoldi D, Guillaume P, et al. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res. 2003;63:5601-5606. (Pubitemid 37139884)
40. Bricard G, Bouzourene H, Martinet O, et al. Naturally acquired MAGE-A10-and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol. 2005;174:1709-1716.
41. Held G, Neumann F, Sturm C, et al. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells. Int J Cancer. 2008;123:1841-1847.
42. He Y, Mao L, Lin Z, et al. Identification of a common HLAA* 0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy. Mol Immunol. 2008;45:2455-2464.
43. Naka N, Joyama S, Tsukamoto Y, et al. Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn. 2005;7:187-197. (Pubitemid 40668301)